GlassScriptPhysician profile
Philip G Mintz
NPI 1043232580
$12,283.36
in general payments reported to CMS, 2019-2025
43 companies · $1,573 in 2025
The $1,573 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,955 · 2020: $868 · 2021: $2,133 · 2022: $1,833 · 2023: $2,018 · 2024: $1,904 · 2025: $1,573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,488 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,487.87 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,595.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,003.41 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $1,619.37 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $624.17 | 2019-2024 | Belsomra, Steglatro, Lagevrio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $620.52 | 2019-2025 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $573.54 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $470.86 | 2019-2025 | |
| Pfizer INC. | $400.34 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $344.67 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $239.72 | 2019-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $195.22 | 2019-2023 | |
| Amarin Pharma, INC. | $180.24 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $168.83 | 2020-2023 | Linzess |
| Biohaven Pharmaceutical Holding Company LTD. | $147.26 | 2022 | |
| Janssen Pharmaceuticals, INC | $138.17 | 2019 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Mintz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.